化浊解毒清幽方加减联合西药治疗幽门螺杆菌阳性晚期胃癌临床研究
DOI:
作者:
作者单位:

作者简介:

通讯作者:

中图分类号:

R735.2

基金项目:


Clinical Study on Modified Huazhuo Jiedu Qingyou Prescription Combined with Western Medicine for Advanced Gastric Cancer with Positive Helicobacter Pylori
Author:
Affiliation:

Fund Project:

  • 摘要
  • |
  • 图/表
  • |
  • 访问统计
  • |
  • 参考文献
  • |
  • 相似文献
  • |
  • 引证文献
  • |
  • 资源附件
  • |
  • 文章评论
    摘要:

    目的:观察化浊解毒清幽方加减联合常规西药治疗幽门螺杆菌(Hp) 阳性晚期胃癌患者的临床疗效。方法:选取Hp 阳性晚期胃癌患者93 例,按随机数字表法分为对照组46 例和观察组47 例。对照组给予常规西药治疗,观察组在对照组基础上给予化浊解毒清幽方加减治疗。比较2 组近期疗效及治疗前后的中医证候积分、外周血T 淋巴细胞亚群(CD3+、CD4+、CD8+、CD4+/CD8+) 变化情况,并比较2 组不良反应发生情况及治疗后的1 年生存率。结果:经秩和检验,观察组近期疗效优于对照组(P<0.05);经过χ2 检验,观察组临床控制率(DCR) 明显高于对照组(P<0.05)。治疗后,2 组中医证候积分较治疗前降低(P<0.05),且观察组中医证候积分低于对照组(P<0.05)。观察组治疗前后外周血CD3+、CD4+、CD8+及CD4+/CD8+比较,差异均无统计学意义(P>0.05);治疗后,对照组CD3+、CD4+及CD4+/CD8+均明显低于治疗前及观察组(P<0.05)。观察组胃肠道反应及骨髓抑制发生率均明显低于对照组(P<0.05);观察组肝肾等脏器损害、皮肤及皮下组织异常、神经毒性反应发生率与对照组比较,差异无统计学意义(P>0.05)。观察组治疗后1 年生存率明显高于对照组(P<0.05)。结论:化浊解毒清幽方加减联合常规西药治疗Hp 阳性晚期胃癌患者,可明显改善患者临床症状,提高临床疗效及1 年生存率,减轻免疫功能损害及不良反应。

    Abstract:

    Abstract: Objective: To observe the clinical effect of modified Huazhuo Jiedu Qingyou prescription combined with routine western medicine for advanced gastric cancer patients with positive helicobacter pylori(Hp). Methods:A total of 93 cases of patients with advanced gastric cancer with positive Hp were selected and divided into the control group and the observation group according to the random number table method,46 and 47 cases in each group respectively. The control group was treated with routine western medicine,and the observation group was additionally treated with modified Huazhuo Jiedu Qingyou prescription based on the treatment of the control group. The changes in Chinese medicine syndrome scores and T lymphocyte subsets including CD3+,CD4+,CD8+ and CD4+/CD8+ in peripheral blood before and after treatment,the recent curative effect, the occurrence of adverse reactions and one- year survival rates after treatment in the two groups were compared. Results:Rank sum test showed that the recent curative effect in the observation group was better than that in the control group(P<0.05). The χ2 test showed that the clinical disease control rate(DCR) in the observation group was significantly higher than that in the control group(P<0.05). After treatment, the Chinese medicine syndrome scores in the two groups were decreased when compared with those before treatment(P<0.05),and the score in the observation group was lower than that in the control group(P<0.05). The comparison of CD3+,CD4+,CD8+ and CD4+/CD8+ in peripheral blood before and after treatment in the observation group showed no significance in the difference(P>0.05);after treatment,the levels of CD3+,CD4+ and CD4+/CD8+ in the control group were significantly lower than those before treatment and those in the observation group(P<0.05). The incidences of gastrointestinal reactions and bone marrow suppression in the observation group were significantly lower than those in the control group(P<0.05);there was no significant difference being found in the comparisons of the incidences of liver and kidney damage, abnormal skin and subcutaneous tissue, and neurotoxicity between the two groups(P>0.05). After treatment, the one- year survival rate in the observation group was significantly higher than that in the control group(P<0.05). Conclusion: The therapy of modified Huazhuo Jiedu Qingyou prescription combined with routine western medicine for advanced gastric cancer patients with positive Hp can significantly improve their clinical symptoms, clinical effect and one- year survival rate, and reduce the damage of immune function and adverse reactions.

    参考文献
    相似文献
    引证文献
引用本文

曾震军,李墨航,郭淑云.化浊解毒清幽方加减联合西药治疗幽门螺杆菌阳性晚期胃癌临床研究[J].新中医,2020,52(18):108-112

复制
分享
文章指标
  • 点击次数:
  • 下载次数:
  • HTML阅读次数:
  • 引用次数:
历史
  • 收稿日期:
  • 最后修改日期:
  • 录用日期:
  • 在线发布日期: 2020-09-20
  • 出版日期: